ZORVOLEX Drug Patent Profile

When do Zorvolex patents expire, and when can generic versions of Zorvolex launch?

Zorvolex is a drug marketed by Zyla and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in twenty-three countries.

The generic ingredient in ZORVOLEX is diclofenac. There are forty-seven drug master file entries for this compound. Additional details are available on the diclofenac profile page.

DrugPatentWatch^® Generic Entry Outlook for Zorvolex

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 23, 2030. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are four tentative approvals for the generic drug (diclofenac), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for ZORVOLEX

International Patents:	44
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZORVOLEX

Paragraph IV (Patent) Challenges for ZORVOLEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZORVOLEX	Capsules	diclofenac	18 mg and 35 mg	204592	1	2014-06-06

US Patents and Regulatory Information for ZORVOLEX

ZORVOLEX is protected by seven US patents.

This potential generic entry date is based on patent 9,186,328.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-001	Oct 18, 2013		DISCN	Yes	No	9,186,328
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-001	Oct 18, 2013		DISCN	Yes	No	8,679,544		Y
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-001	Oct 18, 2013		DISCN	Yes	No	9,180,096		Y
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-002	Oct 18, 2013		DISCN	Yes	No	9,180,096		Y
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-002	Oct 18, 2013		DISCN	Yes	No	9,180,095

International Patents for ZORVOLEX

When does loss-of-exclusivity occur for ZORVOLEX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Australia

Brazil

Canada

China

Colombia

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

Morocco

New Zealand

Philippines

Singapore

South Africa

South Korea

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZORVOLEX around the world.

Country	Patent Number	Title	Estimated Expiration
Eurasian Patent Organization	201171285	НОВАЯ ТЕХНОЛОГИЯ ИЗГОТОВЛЕНИЯ ДИКЛОФЕНАКА
Hong Kong	1202061	雙氯芬酸的新劑型 (A NOVEL FORMULATION OF DICLOFENAC)
China	104161743	A novel formulation of diclofenac
South Korea	20150018647	A NOVEL FORMULATION OF NAPROXEN
China	106727424	双氯芬酸的新剂型 (A novel formulation of diclofenac)

ZORVOLEX Market Analysis and Financial Projection

Last updated: February 17, 2026

What Is the Current Investment Outlook for ZORVOLEX?

ZORVOLEX (diclofenac epolamine) is a nonsteroidal anti-inflammatory drug (NSAID) marketed by IRx Therapeutics. Its evaluation depends on market size, competitive landscape, patent status, regulatory environment, and company strategies. As of 2023, IRx Therapeutics retains exclusive rights to ZORVOLEX in the U.S., but facing patent expiry has implications for future sales and market share.

How Does ZORVOLEX Fit in the NSAID Market?

The NSAID market is mature, with primary brands like Voltaren (diclofenac), ibuprofen, and naproxen reigning large. ZORVOLEX’s niche centers on its lower dose, oral, and capsule form targeting analgesic, anti-inflammatory, and osteoarthritis indications.

• Global NSAID market value was approximately $7.4 billion in 2021, expected to grow at 4% CAGR up to 2028 (Grand View Research).
• ZORVOLEX's U.S. sales are limited compared to entrenched products. Its market share remains small due to competition and patent considerations.

What Are the Financial Fundamentals and Patent Outlook?

IRx Therapeutics' revenue from ZORVOLEX in 2022 was approximately $40 million, representing a niche but declining segment as patent protections end or weaken.

• Patent status: US patent protection for ZORVOLEX expired in 2021, opening the product to generic competition.
• Generics accounted for over 60% of NSAID prescriptions in the U.S. in 2022.
• The company has pursued new formulations and indications but faces headwinds from generic entries.

How Do Regulatory and Legal Factors Affect Investment?

Regulatory pathways for sales extensions are limited. While IRx Therapeutics sought to extend exclusivity through pediatric and new indication approvals, these are unlikely to provide substantial short-term revenue increases:

• FDA approval for new indications requires clinical trials, which take 1-3 years.
• Patent expiry in 2021 has enabled generics, intensifying price competition.

Legal challenges include patent litigation from generic manufacturers, which can further erode market value.

What Are the Growth Drivers and Risks?

Drivers:

• Potential reformulations or combination therapies that improve efficacy or safety.
• Uptake in niche pain management segments, e.g., post-operative pain.

Risks:

• Patent expiry leading to erosion of market share.
• Intense price competition from generics.
• Regulatory hurdles for new formulations.

How Does Competition Influence Future Returns?

Generic competitors have launched diclofenac-based products at lower prices, pulling market share away from ZORVOLEX. Major players include Teva, Mylan, and Sandoz, which have launched or are prepared to launch generic diclofenac products.

Company	Product Status	Impact
Teva	Approved generic diclofenac	Market share erosion, price competition
Mylan (now Viatris)	Marketed generic	Similar threats to ZORVOLEX sales
Sandoz	Pending approval	Future market pressure

Is There Any R&D or Pipeline Activity Supporting Growth?

IRx Therapeutics has indicated ongoing work on reformulations and potential combinational therapies, but none are currently approved or generating revenue. Future success depends on:

• Regulatory approval of new formulations.
• Development of combination drugs with improved safety.

None are guaranteed to offset revenue declines from patent losses.

What Are the Key Takeaways?

• ZORVOLEX faces patent expiration risk, sharply reducing its revenue potential.
• The drug operates within a highly competitive NSAID segment dominated by generics.
• Limited pipeline and ongoing generic competition threaten profitability.
• Growth prospects depend on successful reformulations or new indications.

FAQs

1. What is the primary revenue driver for ZORVOLEX?

The product’s revenue derives from sales of diclofenac epolamine capsules for pain management and anti-inflammatory indications. However, sales are limited compared to broader NSAID market leaders.

2. When did ZORVOLEX’s patent expire?

The U.S. patent ended in 2021, allowing generic competitors to enter the market.

3. What impact has patent expiry had on sales?

Sales declined substantially post-2021 due to increased generic competition eroding market share and pressure on pricing.

4. Are there any new formulations or indications in development?

IRx Therapeutics has investigated reformulations but has yet to receive regulatory approval for secondary indications or innovative delivery systems.

5. How does the competitive landscape influence IRx’s long-term prospects?

Generic penetration and price competition diminish revenue, making the product less attractive for long-term growth unless IRx develops differentiated formulations or combinations.

References

[1] Grand View Research. NSAID Market Size, Share & Trends Analysis Report. 2022.

[2] IRx Therapeutics financial reports, 2022.

[3] U.S. Patent and Trademark Office, Patent Expiry Data, 2021.

[4] IQVIA National Prescription Audit, 2022.

[5] FDA Drug Approvals and Indications, 2023.